Neural Repair Strategies for Parkinson's Disease: Insights from Primate Models
暂无分享,去创建一个
Jeffrey H Kordower | J. Kordower | K. Steece-Collier | Kathy Steece-Collier | Katherine Soderstrom | Jennifer O'Malley | K. Soderstrom | J. O'Malley
[1] Vladimir N. Uversky,et al. Neurotoxicant-induced animal models of Parkinson’s disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration , 2004, Cell and Tissue Research.
[2] D. Jacobowitz,et al. Transient behavioral recovery in hemiparkinsonian primates after adrenal medullary allografts. , 1988, Progress in brain research.
[3] J. Jankovic,et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD , 2003, Neurology.
[4] J. P. Huston,et al. UNILATERAL 6-HYDROXYDOPAMINE LESIONS OF MESO-STRIATAL DOPAMINE NEURONS AND THEIR PHYSIOLOGICAL SEQUELAE , 1996, Progress in Neurobiology.
[5] L. Olson,et al. Electrophysiology and cytology of hippocampal formation transplants in the anterior chamber of the eye. II. Cholinergic mechanisms , 1977, Brain Research.
[6] S. Dunnett,et al. 6-Hydroxydopamine Lesions of Nigrostriatal Neurons as an Animal Model of Parkinson’s Disease , 1994 .
[7] Richard Grondin,et al. Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. , 2002, Brain : a journal of neurology.
[8] M. Chesselet,et al. Variable effects of chronic subcutaneous administration of rotenone on striatal histology , 2004, The Journal of comparative neurology.
[9] J Q Trojanowski,et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. , 2001, The New England journal of medicine.
[10] W. Longstreth,et al. Pesticides and risk of Parkinson disease: a population-based case-control study. , 2005, Archives of neurology.
[11] T. Ljungberg,et al. Electrophysiological and cytological studies of brain homografts in the anterior chamber of the eye: maturation of cerebellar cortex in oculo. , 1974, Brain research.
[12] J. Sagen,et al. Robust survival of isolated bovine adrenal chromaffin cells following intrastriatal transplantation: a novel hypothesis of adrenal graft viability , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[13] O. Hornykiewicz,et al. The neurotoxin MPTP does not reproduce in the rhesus monkey the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson's disease , 1988, Neuroscience Letters.
[14] D. Eidelberg,et al. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation. , 2001, Human gene therapy.
[15] V. Uversky,et al. The Herbicide Paraquat Causes Up-regulation and Aggregation of α-Synuclein in Mice , 2002, The Journal of Biological Chemistry.
[16] Cheryl D. DiCarlo,et al. Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone , 2004, Experimental Neurology.
[17] Y. Iris Chen,et al. Mapping of brain function after MPTP-induced neurotoxicity in a primate Parkinson's disease model , 2003, NeuroImage.
[18] A. Benabid,et al. Bilateral subthalamic nucleus stimulation for severe Parkinson's disease , 1995, Movement disorders : official journal of the Movement Disorder Society.
[19] A. Kupsch,et al. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline , 2001, Journal of Neural Transmission.
[20] Stanley Fahn,et al. Dyskinesia after fetal cell transplantation for parkinsonism: A PET study , 2002, Annals of neurology.
[21] A. Benabid,et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. , 1998, The New England journal of medicine.
[22] Haruhiko Kishima,et al. Functional Recovery in a Primate Model of Parkinson's Disease following Motor Cortex Stimulation , 2004, Neuron.
[23] M. Polymeropoulos,et al. Genetics of Parkinson's disease. , 1997, Human molecular genetics.
[24] A. Björklund,et al. Growth of transplanted monoaminergic neurones into the adult hippocampus along the perforant path , 1976, Nature.
[25] R. Ridley,et al. A comparison of the behavioural effects of embryonic nigral grafts in the caudate nucleus and in the putamen of marmosets with unilateral 6-OHDA lesions , 2004, Experimental Brain Research.
[26] G. Wooten,et al. Differential localization of A2a adenosine receptor mRNA with D1 and D2 dopamine receptor mRNA in striatal output pathways following a selective lesion of striatonigral neurons , 1993, Brain Research.
[27] R. Penn,et al. Putative chromaffin cell survival and enhanced host‐derived TH‐Fiber innervation following a functional adrenal medulla autograft for Parkinson's disease , 1991, Annals of neurology.
[28] H. Wang,et al. Study of adrenal medullary tissue transplantation to striatum in parkinsonism. , 1988, Progress in brain research.
[29] R. Roth,et al. Severe long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the vervet monkey (Cercopithecus aethiops sabaeus) , 1997, Neuroscience.
[30] S. Gill,et al. Intraputamenal infusion of glial cell line–derived neurotrophic factor in PD: A two‐year outcome study , 2005, Annals of neurology.
[31] D. D. Di Monte,et al. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model , 2000, Movement disorders : official journal of the Movement Disorder Society.
[32] I. Miyazaki,et al. Rotenone induces aggregation of γ-tubulin protein and subsequent disorganization of the centrosome: Relevance to formation of inclusion bodies and neurodegeneration , 2005, Neuroscience.
[33] H. Braak,et al. Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.
[34] N. Déglon,et al. Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease , 2004, Neurobiology of Disease.
[35] P. Follesa,et al. Topographical localization of glial cell line-derived neurotrophic factor in the human brain stem: an immunohistochemical study of prenatal, neonatal and adult brains , 2002, Journal of Chemical Neuroanatomy.
[36] H. Bergman,et al. The primate subthalamic nucleus. I. Functional properties in intact animals. , 1994, Journal of neurophysiology.
[37] J. Bloch,et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. , 2000, Science.
[38] Anders Björklund,et al. Characterization of Behavioral and Neurodegenerative Changes Following Partial Lesions of the Nigrostriatal Dopamine System Induced by Intrastriatal 6-Hydroxydopamine in the Rat , 1998, Experimental Neurology.
[39] T. Peng,et al. Mitochondrial dysfunction in Parkinson's disease. , 1999, Biochemical Society symposium.
[40] C. Sachs,et al. Mechanisms of action of 6-hydroxydopamine. , 1975, Biochemical Pharmacology.
[41] U. Ungerstedt,et al. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. , 1968, European journal of pharmacology.
[42] A. Björklund,et al. Migration patterns and phenotypic differentiation of long-term expanded human neural progenitor cells after transplantation into the adult rat brain. , 2002, Brain research. Developmental brain research.
[43] M. Muenter,et al. Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature , 2001, Movement disorders : official journal of the Movement Disorder Society.
[44] E. Richfield,et al. Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: environmental risk factors for Parkinson’s disease? , 2000, Brain Research.
[45] B Bioulac,et al. Relationship between the Appearance of Symptoms and the Level of Nigrostriatal Degeneration in a Progressive 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease , 2001, The Journal of Neuroscience.
[46] S. Dunnett,et al. Long-Term Survival of Human Central Nervous System Progenitor Cells Transplanted into a Rat Model of Parkinson's Disease , 1997, Experimental Neurology.
[47] R. Bakay,et al. Biochemical and Behavioral Correction of MPTP Parkinson‐like Syndrome by Fetal Cell Transplantation a , 1987, Annals of the New York Academy of Sciences.
[48] E. Oldfield,et al. Long-term evaluation of hemiparkinsonian monkeys after adrenal autografting or cavitation alone. , 1990, Journal of neurosurgery.
[49] A. Björklund,et al. Nigrostriatal α-synucleinopathy induced by viral vector-mediated overexpression of human α-synuclein: A new primate model of Parkinson's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[50] Timothy Sendera,et al. Clinicopathological findings following intraventricular glial‐derived neurotrophic factor treatment in a patient with Parkinson's disease , 1999, Annals of neurology.
[51] M. Mishkin,et al. Adrènal medulla grafts survice and exhibit catecholamine-specific fluorescence in the primate brain , 1984, Experimental Neurology.
[52] R. Penn,et al. The adrenal medullary transplant operation for Parkinson's disease: clinical observations in five patients. , 1988, Neurosurgery.
[53] R. Ridley,et al. Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus) , 2003, Experimental Neurology.
[54] Joseph Jankovic,et al. Motor fluctuations and dyskinesias in Parkinson's disease: Clinical manifestations , 2005, Movement disorders : official journal of the Movement Disorder Society.
[55] D. Togasaki,et al. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by instrastriatal injection of 6-hydroxydopamine , 1995, Neuroscience.
[56] E. Tiffany-Castiglioni,et al. The Bipyridyl Herbicide Paraquat Produces Oxidative Stress-Mediated Toxicity in Human Neuroblastoma SH-SY5Y Cells: Relevance to the Dopaminergic Pathogenesis , 2005, Journal of toxicology and environmental health. Part A.
[57] J. Deniau,et al. Spontaneous and Evoked Activity of Substantia Nigra Pars Reticulata Neurons during High-Frequency Stimulation of the Subthalamic Nucleus , 2003, The Journal of Neuroscience.
[58] G. Nikkhah,et al. Improved graft survival and striatal reinnervation by microtransplantation of fetal nigral cell suspensions in the rat Parkinson model , 1994, Brain Research.
[59] C. Marsden,et al. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. , 2000, Brain : a journal of neurology.
[60] L. Olson,et al. Early prenatal ontogeny of central monoamine neurons in the rat: Fluorescence histochemical observations , 2004, Zeitschrift für Anatomie und Entwicklungsgeschichte.
[61] D. Cory-Slechta,et al. Modulation of antioxidant defense systems by the environmental pesticide maneb in dopaminergic cells. , 2005, Neurotoxicology.
[62] K. Mewes,et al. The Subthalamic Nucleus and Tremor in Parkinson's Disease , 2008, Movement disorders : official journal of the Movement Disorder Society.
[63] R. Roth,et al. Intrastriatal grafts from multiple donors do not result in a proportional increase in survival of dopamine neurons in nonhuman primates. , 1998, Cell transplantation.
[64] A. Albanese,et al. Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: Behavioural, morphological and biochemical correlates , 1993, Neuroscience.
[65] R. Roth,et al. Sham surgery does not ameliorate MPTP-induced behavioral deficits in monkeys. , 1995, Cell transplantation.
[66] A. Björklund,et al. Parkinson-Like Neurodegeneration Induced by Targeted Overexpression of α-Synuclein in the Nigrostriatal System , 2002, The Journal of Neuroscience.
[67] D. Jacobowitz,et al. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[68] S. Haber,et al. Transplantation of fetal dopamine neurons in primate brain reverses MPTP induced parkinsonism. , 1987, Progress in brain research.
[69] P. Calabresi,et al. Subthalamic nucleus lesion reverses motor abnormalities and striatal glutamatergic overactivity in experimental parkinsonism , 2005, Neuroscience.
[70] R. Roth,et al. Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment , 1999, Neuroscience.
[71] J. Vitek,et al. Stimulation of the Subthalamic Nucleus Changes the Firing Pattern of Pallidal Neurons , 2003, The Journal of Neuroscience.
[72] Nobuyuki Itoh,et al. Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model. , 2005, The Journal of clinical investigation.
[73] R. Roth,et al. Cryopreservation, culture, and transplantation of human fetal mesencephalic tissue into monkeys. , 1988, Science.
[74] H. Shibasaki,et al. Immunohistochemical localization of glial cell line-derived neurotrophic factor in the human central nervous system , 2000, Neuroscience.
[75] W. Tatton,et al. Etiology and pathogenesis of Parkinson's disease. , 1999, Annual review of neuroscience.
[76] Philippe Hantraye,et al. MPTP induces alpha‐synuclein aggregation in the substantia nigra of baboons , 2000, Neuroreport.
[77] Vesna Sossi,et al. A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease , 2003, Annals of neurology.
[78] J. Eberling,et al. Overlesioned hemiparkinsonian non human primate model: correlation between clinical, neurochemical and histochemical changes. , 2003, Frontiers in bioscience : a journal and virtual library.
[79] R. Penn,et al. Multicenter study of autologous adrenal medullary transplantation to the corpus striatum in patients with advanced Parkinson's disease. , 1989, The New England journal of medicine.
[80] G. Gerhardt,et al. Increased dopamine clearance in the non-lesioned striatum of rhesus monkeys with unilateral 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) striatal lesions , 1995, Neuroscience Letters.
[81] P. Jenner,et al. The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease. , 2003, Parkinsonism & related disorders.
[82] Andisheh Eslamboli. Marmoset monkey models of Parkinson's disease: Which model, when and why? , 2005, Brain Research Bulletin.
[83] E. Oldfield,et al. Reversal of hemiparkinsonian syndrome in nonhuman primates by amnion implantation into caudate nucleus. , 1994, Journal of neurosurgery.
[84] P. Aebischer,et al. α-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[85] J. Kordower,et al. Adrenal medullary tissue grafting in Parkinson's disease. , 1988, Journal of neurosurgery.
[86] J. Kordower,et al. Human neural progenitors deliver glial cell line-derived neurotrophic factor to parkinsonian rodents and aged primates , 2006, Gene Therapy.
[87] R. Barker,et al. Survival of Nigral Grafts within the Striatum of Marmosets with 6-Ohda Lesions Depends Critically on Donor Embryo Age , 1997 .
[88] D. Hansel,et al. Subthalamic high frequency stimulation resets subthalamic firing and reduces abnormal oscillations. , 2005, Brain : a journal of neurology.
[89] A L Benabid,et al. Treatment of tremor in Parkinson's disease by subthalamic nucleus stimulation , 1998, Movement disorders : official journal of the Movement Disorder Society.
[90] Y. Mitsumoto,et al. Spontaneous regeneration of nigrostriatal dopaminergic neurons in MPTP-treated C57BL/6 mice. , 1998, Biochemical and biophysical research communications.
[91] Gary W Miller,et al. Paraquat neurotoxicity is distinct from that of MPTP and rotenone. , 2005, Toxicological sciences : an official journal of the Society of Toxicology.
[92] R. Ridley,et al. Behavioral Assessment of the Effects of Embryonic Nigral Grafts in Marmosets with Unilateral 6-OHDA Lesions of the Nigrostriatal Pathway , 1994, Experimental Neurology.
[93] G. Nikkhah,et al. A microtransplantation approach for cell suspension grafting in the rat parkinson model: A detailed account of the methodology , 1994, Neuroscience.
[94] L. Tremblay,et al. Quantitative analysis of dopaminergic loss in relation to functional territories in MPTP‐treated monkeys , 2003, The European journal of neuroscience.
[95] T. Montine,et al. Manganese ethylene‐bis‐dithiocarbamate and selective dopaminergic neurodegeneration in rat: a link through mitochondrial dysfunction , 2003, Journal of neurochemistry.
[96] W. Schultz. MPTP-induced parkinsonism in monkeys: mechanism of action, selectivity and pathophysiology. , 1988, General pharmacology.
[97] M. Boscaro,et al. Pharmacologic Management , 2005 .
[98] C. Olanow,et al. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. , 1999, Archives of neurology.
[99] J. Langston,et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.
[100] R. Ridley,et al. Sensorimotor deficits in a unilateral intrastriatal 6-OHDA partial lesion model of Parkinson’s disease in marmoset monkeys , 2003, Experimental Neurology.
[101] A. Bjo¨rklund,et al. Transplantation of central and peripheral monoamine neurons to the adult rat brain: Techniques and conditions for survival , 1976, Brain Research.
[102] G. Petzinger,et al. The parkinsonian toxin 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP): a technical review of its utility and safety , 2001, Journal of neurochemistry.
[103] K. Mohanakumar,et al. Acute intranigral infusion of rotenone in rats causes progressive biochemical lesions in the striatum similar to Parkinson's disease , 2005, Brain Research.
[104] R. Barker,et al. Survival of nigral grafts within the striatum of marmosets with 6-OHDA lesions depends critically on donor embryo age. , 1997, Cell transplantation.
[105] O. Lindvall,et al. Transplantation in Parkinson's disease: Two cases of adrenal medullary grafts to the putamen , 1987, Annals of neurology.
[106] G. Sedvall,et al. Transplantation of adrenal medullary tissue to striatum in parkinsonism. First clinical trials. , 1985, Journal of neurosurgery.
[107] C. Marsden,et al. Sequential bilateral transplantation in Parkinson's disease: effects of the second graft. , 1999, Brain : a journal of neurology.
[108] R. Roth,et al. Fetal Dopamine Cell Survival after Transplantation Is Dramatically Improved at a Critical Donor Gestational Age in Nonhuman Primates , 1993, Experimental Neurology.
[109] P. Sanberg,et al. Neural transplantation for treatment of Parkinson's disease. , 2002, Drug discovery today.
[110] Todd Sherer,et al. Rotenone Model of Parkinson Disease , 2005, Journal of Biological Chemistry.
[111] T. Aziz,et al. Lesioning the Subthalamic Nucleus in the Treatment of Parkinson’s Disease , 2002, Stereotactic and Functional Neurosurgery.
[112] R. Roth,et al. Intrastriatal Grafts from Multiple Donors do not Result in a Proportional Increase in Survival of Dopamine Neurons in Nonhuman Primates , 1998 .
[113] W. Langston,et al. α-Synuclein expression in the substantia nigra of MPTP-lesioned non-human primates , 2005, Neurobiology of Disease.
[114] A. Akaike,et al. FGF-20, a novel neurotrophic factor, preferentially expressed in the substantia nigra pars compacta of rat brain. , 2000, Biochemical and biophysical research communications.
[115] Clive N Svendsen,et al. A new method for the rapid and long term growth of human neural precursor cells , 1998, Journal of Neuroscience Methods.
[116] D. Brooks,et al. Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease , 2003, Nature Medicine.
[117] E. Richfield,et al. A Fetal Risk Factor for Parkinson’s Disease , 2004, Developmental Neuroscience.